Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036188 · ClinicalTrials.gov registry record · Early Phase 1
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
A Early Phase 1 study of Plaque Psoriasis and Vitamin D3, sponsored by Wright State University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04036188 is a Early Phase 1 study of Plaque Psoriasis and Vitamin D3 that is actively recruiting participants, run by Wright State University. The registered enrollment target is 24 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04036188, a Early Phase 1 study of Plaque Psoriasis and Vitamin D3, is actively recruiting participants, sponsored by Wright State University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Vitamin D3
- DRUG Triamcinolone
Study Locations (1)
Ohio
- Wright State Physicians - Fairborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04036188
The ClinicalTrials.gov registry entry for NCT04036188 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The listed sponsor is Wright State University, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04036188 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04036188 about?
NCT04036188 is a clinical study titled "Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis". These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomi...
What is the current status of trial NCT04036188?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2019-10-16. Estimated completion is 2026-12.
What conditions does trial NCT04036188 study?
This clinical trial studies the following conditions: Plaque Psoriasis, Vitamin D3.
What interventions are being tested in trial NCT04036188?
The interventions under investigation include: Placebo (DRUG), Vitamin D3 (DIETARY_SUPPLEMENT), Triamcinolone (DRUG).
Who is sponsoring clinical trial NCT04036188?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04036188 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
RECRUITING · Phase 1
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.